# Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial)

> **NCT04315896** · PHASE3 · COMPLETED · sponsor: **National Institute of Respiratory Diseases, Mexico** · enrollment: 320 (actual)

## Conditions studied

- COVID-19
- Severe Acute Respiratory Syndrome

## Interventions

- **DRUG:** Hydroxychloroquine
- **DRUG:** Placebo oral tablet

## Key facts

- **NCT ID:** NCT04315896
- **Lead sponsor:** National Institute of Respiratory Diseases, Mexico
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-14
- **Primary completion:** 2020-07-01
- **Final completion:** 2020-08-15
- **Target enrollment:** 320 (ACTUAL)
- **Last updated:** 2022-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04315896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04315896, "Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04315896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*